These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Defining "True and Non-Misleading" for Pharmaceutical Promotion. Hey SP, Kesselheim AS. J Law Med Ethics; 2018 Jun; 46(2):552-554. PubMed ID: 30146990 [No Abstract] [Full Text] [Related]
24. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory. Blackwell AE, Beck JM, Dechert, L.L.P, Philadelphia, USA. Food Drug Law J; 2003 Jun; 58(3):439-62. PubMed ID: 14626985 [No Abstract] [Full Text] [Related]
25. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm. Orentlicher D. Am J Law Med; 2011 Jun; 37(2-3):299-314. PubMed ID: 21847883 [No Abstract] [Full Text] [Related]
26. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012. Vilhelmsson A, Davis C, Mulinari S. PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151 [Abstract] [Full Text] [Related]
27. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation. Stewart KA, Neumann PJ. Value Health; 2002 Jan; 5(5):390-7. PubMed ID: 12201856 [Abstract] [Full Text] [Related]
30. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation? Mackey TK, Liang BA. Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416 [No Abstract] [Full Text] [Related]
31. The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis. Evans GW, Friede AI, Pfizer Inc, New York, NY, USA. Food Drug Law J; 2003 Jun; 58(3):365-437. PubMed ID: 14626984 [No Abstract] [Full Text] [Related]
32. Prescription drug advertising--should states regulate what is false and misleading? Shaeffer J. Food Drug Law J; 2003 Jun; 58(4):629-48. PubMed ID: 15027454 [No Abstract] [Full Text] [Related]
36. Examining the FDA's oversight of direct-to-consumer advertising. Gahart MT, Duhamel LM, Dievler A, Price R. Health Aff (Millwood); 2003 Jun; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243 [Abstract] [Full Text] [Related]
37. Drug risks and free speech--can Congress ban consumer drug ads? Shuchman M. N Engl J Med; 2007 May 31; 356(22):2236-9. PubMed ID: 17476002 [No Abstract] [Full Text] [Related]
38. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters. Kim H. Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465 [Abstract] [Full Text] [Related]
39. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns. Sharfstein JM, Charo A. JAMA; 2015 Nov 03; 314(17):1795-6. PubMed ID: 26367520 [No Abstract] [Full Text] [Related]
40. Back to first principles: a new model for the regulation of drug promotion. Bennett A, Jiménez F, Fields LE, Oyster J. J Law Biosci; 2015 Jul 03; 2(2):168-212. PubMed ID: 27774195 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]